Analyst Ratings For Pacira BioSciences
Portfolio Pulse from Benzinga Insights
Analyst ratings for Pacira BioSciences (NASDAQ:PCRX) show a mix of bullish and bearish perspectives with a recent average price target of $46.67, down from $49.00. The company's financials indicate positive revenue growth, strong profitability, and efficient asset management but highlight challenges in debt management. Pacira BioSciences specializes in non-opioid pain management solutions, with three commercialized treatments.
May 08, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analyst ratings for Pacira BioSciences show a mix of bullish and bearish views, with a recent decrease in the average price target to $46.67 from $49.00. The company's financials reveal positive revenue growth and strong profitability metrics, but also highlight a high debt-to-equity ratio.
The mixed analyst ratings with a slight decrease in the average price target suggest a cautious but not negative outlook for PCRX in the short term. The company's strong financial performance indicators, such as revenue growth and profitability, support a stable outlook. However, the high debt-to-equity ratio could be a concern for some investors, potentially limiting the stock's upside in the short term. The overall neutral score reflects these balanced factors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100